...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia.
【24h】

miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia.

机译:miR-181b是慢性淋巴细胞性白血病疾病进展的生物标志物。

获取原文
获取原文并翻译 | 示例

摘要

MicroRNAs play a crucial role in chronic lymphocytic leukemia. We investigated whether microRNAs can discriminate patients with a progressive disease from patients with a stable disease. We analyzed microRNA expression on leukemic cells isolated from 358 sequential samples of 114 patients with either stable or progressive disease. We found that during the course of the disease the expression values of miR-181b, the most dysregulated microRNA, decreased in samples of patients with a progressive (P < .001, training and validation sets) but not in samples of patients with a stable disease (P = .3, training set; P = .2, validation set) over time. A drop of >/= 50% between sequential samples and/or a miR-181b value
机译:MicroRNA在慢性淋巴细胞性白血病中起关键作用。我们调查了microRNA是否可以区分进行性疾病患者和稳定疾病患者。我们分析了114例稳定或进行性疾病患者的358个连续样本中分离出的白血病细胞上的microRNA表达。我们发现,在疾病过程中,进展最严重的患者样本中miR-181b(微RNA失调最严重)的表达值下降(P <.001,训练和验证集),而稳定的患者样本则未下降疾病(P = .3,训练集; P = .2,验证集)随着时间的推移。在开始的时间点之间,连续样本之间的下降> / = 50%和/或miR-181b值

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号